Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Castelnau Le Lez, France Clinical Trials

A listing of Castelnau Le Lez, France clinical trials actively recruiting patients volunteers.

Found (133) clinical trials

Identification of Cardiovascular Risk Factors Linked to Renal Failure Progression

The aim of this study is to appreciate the relationship between: - extension of coronary calcifications and chronic renal failure progression - extension of coronary calcifications and levels of osteoprotegerin (bone disease marker) - cardiovascular risk factors and coronary calcifications - cardiovascular risk factors and existence of cardiovascular diseases

Phase N/A

1.85 miles

Learn More »

High Dose Therapy Followed by Autologous Transplantation for Myeloma Patients With Severe Renal Impairment

RI is associated with poor prognosis and short median survival (32 months vs 55 months for MM patients with normal renal function). Thus, RI remains a major challenge for hematologists, including decisions on optimal anti-myeloma therapy, potential dialysis, supportive care and quality of life. The combination of a proteasome inhibitor …

Phase N/A

1.85 miles

Learn More »

Influence of Socio-Economic Factor on Net Survival in Patients With Multiple Sclerosis in France ( ECOVIMUS).

Background: In comparison to general population, persons with Multiple Sclerosis have a higher risk to premature death with an estimate reduced life expectancy from 7 to 14 years. However, risk factors of mortality in MS are not well identified and well known. Following the example of studies carry on cancers …

Phase N/A

1.85 miles

Learn More »

Dat'Aids Prevention

DatAIDS prevention is a cohort study of HIV prevention in over 23 HIV sites in France including overseas, aiming to describe HIV prevention in every aspect including HIV screening, STI and hepatitis screening, post-exposure prophylaxis and pre-exposure prophylaxis

Phase N/A

1.85 miles

Learn More »

Use Lay Language. HA Score to Identify Myeloma Patients Who Could Benefit From HDACi Treatment

Panobinostat is a potent oral histone deacetylase inhibitor that alters gene expression through epigenetic mechanisms and inhibits protein degradation. It was recently approved by the US Food and Drug Administration for use in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma (MM) who have received 2 prior …

Phase N/A

1.85 miles

Learn More »

OFSEP High Definition Cohort

For neurologists and patients, it appears that one major unmet need, beside of course a cure to multiple sclerosis (MS), is to better appreciate the causal factors of disease progression, and even to obtain reliable predictive tools that could apply on the individual level and at different key moments in …

Phase N/A

1.85 miles

Learn More »

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

The study will capture post-marketing safety data on patients treated with eculizumab or ravulizumab. Additionally, the study will collect information on the progression of disease in all patients.

Phase N/A

1.85 miles

Learn More »

Product Surveillance Registry

The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge …

Phase N/A

1.85 miles

Learn More »

Using a New Calibrated Tool in Specific Language and Learning Disorders : the BMTi

The group of experts at High Authority of Health (HAS) has defined the places of first and second-line workers in specific disorders of development and learning, as defined in the international diagnostic classifications CIM 11 and DSM 5. The referral to a second-level structure, a multidisciplinary structure in charge of …

Phase N/A

1.85 miles

Learn More »

Influence of Intestinal Microbiota Implantation in Preterm Infants on Microbiota and Immune Orientation at 3 Years

The secondary objectives are to study the links between changes of the intestinal microbiota premature infants in terms of: changing diversity of the microbiota in the first 6 weeks of life; changes in the bacterial community (UniFrac study) during the first 6 weeks of life; diversity of the microbiota up …

Phase N/A

1.85 miles

Learn More »